CB1 receptor-independent actions of SR141716 on G-protein signaling: Coapplication with the μ-opioid agonist tyr-D-ala-gly-(NMe)phe- gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in μ-opioid receptor-Chinese hamster ovary cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 2, 2009, Pages 567-574

  Cinar, Resat ^a   Szücs, Mária ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1 METHANESULFONYLAMINO 4 HEXYN 6 YL) 6A,7,10,10A TETRAHYDRO 6,6,9 TRIMETHYL 6H DIBENZO[B,D]PYRAN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MU OPIATE RECEPTOR; NALOXONE; O 2050; PERTUSSIS TOXIN; RIMONABANT; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CHO CELL; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; KNOCKOUT MOUSE; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; COMPARATIVE STUDY; CRICETULUS; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HAMSTER; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GTP-BINDING PROTEINS; MALE; MICE; MICE, KNOCKOUT; PERTUSSIS TOXIN; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 67651008656     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.152710     Document Type: Article

References (33)

1. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, and Kunos G (2005) Evidence for novel cannabinoid receptors. Pharmacol Ther 106:133-145.
2. Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, and Santoro A (2007) Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 71:1445-1456. (Pubitemid 47010897)
3. Bloom AS, Edgemond WS, and Moldvan JC (1997) Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. Neurochem Res 22:563-568.
4. Bradford MM (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Breivogel CS, Griffin G, Di Marzo V, and Martin BR (2001) Evidence for a new G protein-coupled receptor in mouse brain. Mol Pharmacol 60:155-163. (Pubitemid 32595243)
6. Canals M and Milligan G (2008) Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed mu opioid receptors. J Biol Chem 283:11424-11434.
7. Chakrabarti S, Regec A, and Gintzler AR (2005) Biochemical demonstration of mu-opioid receptor association with Gs alpha: enhancement following morphine exposure. Brain Res Mol Brain Res 135:217-224. (Pubitemid 40602413)
8. Childers SR (1991) Opioid-coupled second messenger systems. Life Sci 48:1991-2003.
9. B receptor interactions in rat hippocampal membranes. Neurochem Int 52:1402-1409.
10. B receptors in rat brain hippocampal membranes (Abstract). FEBS J 273 (Suppl 1):91.
11. 35S]GTPγS binding in mouse brain cerebellum and piriform cortex membranes. Br J Pharmacol 154:1349-1358.
12. di Bosco AM, Grieco P, Diurno MV, Campiglia P, Novellino E, and Mazzoni O (2008) Binding site of loperamide: automated docking of loperamide in human μ- and δ-opioid receptors. Chem Biol Drug Des 71:328-335. (Pubitemid 351347788)
13. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO, et al. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284:291-297. (Pubitemid 28109558)
14. Gibson HE, Edwards JG, Page RS, Van Hook MJ, and Kauer JA (2008) TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 57:746-759.
15. Glass M and Northup JK (1999) Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol Pharmacol 56:1362-1369.
16. 2+ signaling and NFAT activation. FASEB J 23:183-193.
17. Howlett AC (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27:429-436.
18. Kane BE, Svensson B, and Ferguson DM (2006) Molecular recognition of opioid receptor ligands. AAPS J 8:E126-E137.
19. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404. (Pubitemid 129501104)
20. Liu JG and Prather PL (2001) Chronic exposure to μ-opioid agonists produces constitutive activation of μ-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol Pharmacol 60:53-62.
21. MacLennan SJ, Reynen PH, Kwan J, and Bonhaus DW (1998) Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 124:619-622. (Pubitemid 28276796)
22. Milligan G (2003) Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64:1271-1276.
23. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
24. Pickel VM, Chan J, Kash TL, Rodríguez JJ, and MacKie K (2004) Compartment-specific localization of cannabinoid 1 (CB1) and μ-opioid receptors in rat nucleus accumbens. Neuroscience 127:101-112. (Pubitemid 38829156)
25. Rios C, Gomes I, and Devi LA (2006) μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148:387-395.
26. Savinainen JR, Saario SM, Niemi R, Järvinen T, and Laitinen JT (2003) An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140:1451-1459. (Pubitemid 38067852)
27. Sim-Selley LJ, Brunk LK, and Selley DE (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135-143.
28. Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, Peng Y, Pang Y, Olszewska T, Olzewska T, et al. (2008) The novel cannabinoid CB(1) receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946-955. (Pubitemid 351252707)
29. Spiegel AM (1996) Mutations in G proteins and G protein-coupled receptors in endocrine disease. J Clin Endocrinol Metab 81:2434-2442. (Pubitemid 26240257)
30. Szücs M, Boda K, and Gintzler AR (2004) Dual effects of DAMGO [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr- Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling. J Pharmacol Exp Ther 310:256-262.
31. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS, and Chen YA (2009) Lipid G-protein coupled receptor ligand identification using β-arrestin pathhunter™ assay. J Biol Chem 284:12328-12338.
32. Waldhoer M, Bartlett SE, and Whistler JL (2004) Opioid receptors. Annu Rev Biochem 73:953-990.
33. Wang D, Raehal KM, Bilsky EJ, and Sadée W (2001) Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-1600. (Pubitemid 32574494)